Pay in 4 interest-free payments of $6.34 Learn more
Ships within 48 hours · Estimated delivery Sep 25 - Sep 30
Findings published in a preprint from a phase I clinical trial on the GLP1glucagon receptor co-agonist NN1177 in adults with overweight or obesity have raised problems with deterioration of glucose tolerance and other safety concerns, despite inducing weight loss, which illustrates the difficulties in getting the agonist balance right during the preclinical development of co-agonist therapies 6,7
Panther EJ, Dodd W, Clark A, Lucke-Wold B
used off-label for adult GH deficiency management), tesamorelin (FDA-approved for HIV-associated lipodystrophy under the brand Egrifta SV), and mecasermin (approved for severe primary IGF-1 deficiency in children) [15, 19]
In terms of gender distribution, 60.0% of the subjects and 69.1% of the healthy controls were female
US$ 27.33
US$ 28.83
US$ 21.03
US$ 29.73
US$ 25.25
